<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 10-Q

[ X ]    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
         THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended April 30, 2001

[   ]   TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF
        THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from                 to                    .
                               ---------------    -------------------

                         COMMISSION FILE NUMBER: 0-25169
                                                 -------

                        GENEREX BIOTECHNOLOGY CORPORATION
             -------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                                        82-0490211
---------------------------                    ---------------------------------
(State or other jurisdiction of                (IRS Employer Identification No.)
 incorporation or organization)

                           33 HARBOR SQUARE, SUITE 202
                                TORONTO, ONTARIO
                                 CANADA M5J 2G2
             -------------------------------------------------------
                    (Address of principal executive offices)

                                  416/364-2551
             -------------------------------------------------------
              (Registrant's telephone number, including area code)

                                 Not applicable
--------------------------------------------------------------------------------
               (Former name, former address and former fiscal year
                          if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.     [X]      Yes              [  ]     No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

The number of outstanding shares of the registrant's Common Stock, par value
$.001, was 19,290,518 as of April 30, 2001.


<PAGE>


               GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
                                      INDEX


PART I:   FINANCIAL INFORMATION

Item 1.   Consolidated Financial Statements -- unaudited

          Consolidated Balance Sheets --
          April 30, 2001 and July 31, 2000 ..............................    3

          Consolidated Statements of Operations -- for the three month
          periods ended April 30, 2001 and 2000, the nine month periods
          ended April 30, 2001 and 2000, and cumulative from November 2,
          1995 to April 30, 2001.........................................    4

          Consolidated Statements of Cash Flows -- For the nine-month
          periods ended April 30, 2001 and 2000, and cumulative from
          November 2, 1995 to April 30, 2001.............................    5

          Notes to Consolidated Financial Statements.....................    6

Item 2.   Management's Discussion and Analysis of Financial
          Condition and Results of Operations............................   11

Item 3.   Quantitative and Qualitative Disclosures
          About Market Risk..............................................   15

Item 4.   Submission of Matters to a Vote of Security
          Holders........................................................   16


PART II:  OTHER INFORMATION

Item 1.   Legal Proceedings..............................................   17

Item 6.   Exhibits and Reports on Form 8-K...............................   17

Signatures...............................................................   18




                                       2
<PAGE>



Item 1.  Consolidated financial statements

               GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                           CONSOLIDATED BALANCE SHEETS
                                   (UNAUDITED)
<TABLE>
<CAPTION>

                                                                                    April 30,       July 31,
                                                                                  ------------    ------------
                                                                                      2001           2000
                                                                                  ------------    ------------
         ASSETS

Current Assets:
<S>                                                                               <C>             <C>
   Cash and cash equivalents                                                      $  1,795,925    $  3,204,905
   Short-term investments                                                           26,960,524       3,966,263
   Miscellaneous receivables                                                              --            16,138
   Other current assets                                                                189,439          99,041
                                                                                  ------------    ------------
         Total Current Assets                                                       28,945,888       7,286,347

Property and Equipment, Net                                                          3,700,372       2,395,867
Patents, Net                                                                           413,949         267,369
Deposits                                                                                19,274          47,914
Deferred Offering Costs                                                              3,406,196            --
Due From Related Parties                                                               329,748         343,773
                                                                                  ------------    ------------

         TOTAL ASSETS                                                             $ 36,815,427    $ 10,341,270
                                                                                  ============    ============

         LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
   Accounts payable and accrued expenses                                          $    794,075    $  1,204,282
   Current maturities of long-term debt                                                  9,305           9,404
                                                                                  ------------    ------------
         Total Current Liabilities                                                     803,380       1,213,686

Long-Term Debt, Less Current Maturities                                                680,302         712,559
Commitments and Contingencies

Stockholders' Equity:
   Preferred stock, $.001 par value; authorized 1,000,000
     shares, no shares issued and outstanding at
     April 30, 2001 and July 31, 2000                                                     --              --
   Special Voting Rights Preferred stock, $.001 par value;
     authorized, issued and outstanding 1,000 shares at
     April 30, 2001 and at July 31, 2000                                                     1               1
   Series A Preferred stock, $.001 par value; authorized
     1,512 and -0- shares, issued and outstanding 1,000
     and -0- shares at April 30, 2001 and July 31, 2000,
     respectively                                                                            1            --
   Common stock, $.001 par value; authorized 50,000,000
     shares, issued and outstanding 19,294,410 and
     16,326,333 shares at April 30, 2001 and July 31,
     2000, respectively                                                                 19,294          16,327
   Additional paid-in capital                                                       75,785,956      30,435,066
   Notes receivable - common stock                                                    (308,992)        (54,118)
   Deficit accumulated during the development stage                                (39,880,334)    (21,816,725)
   Accumulated other comprehensive loss                                               (284,181)       (165,526)
                                                                                  ------------    ------------
         Total Stockholders' Equity                                                 35,331,745       8,415,025
                                                                                  ------------    ------------

         TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                               $ 36,815,427    $ 10,341,270
                                                                                  ============    ============
</TABLE>

                 The Notes to Consolidated Financial Statements
                    are an integral part of these statements.


                                       3
<PAGE>


               GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (UNAUDITED)

<TABLE>
<CAPTION>

                                                                                                               Cumulative From
                                                 For the Three Months Ended     For the Nine Months Ended      November 2, 1995
                                                                                                              (Date of Inception)
                                                          April 30,                       April 30,              to April 30,
                                                ----------------------------    ----------------------------  ------------------
                                                   2001            2000            2001             2000             2001
                                                ------------    ------------    ------------    ------------  ------------------

<S>                                             <C>             <C>             <C>             <C>              <C>
Contract Research Revenues                      $       --      $       --      $  1,000,000    $       --       $  1,000,000

Operating Expenses:
   Research and development                          718,385       1,084,295      17,586,294       2,520,467       24,532,330
   Research and development - related party             --              --              --              --            220,218
   General and administrative                      2,369,037       1,238,806       5,518,852       3,898,972       19,982,642
   General and administrative - related party           --              --              --              --            314,328
                                                ------------    ------------    ------------    ------------     ------------

       Total Operating Expenses                    3,087,422       2,323,101      23,105,146       6,419,439       45,049,518
                                                ------------    ------------    ------------    ------------     ------------

Operating Loss                                    (3,087,422)     (2,323,101)    (22,105,146)     (6,419,439)     (44,049,518)

Other Income (Expense):
   Minority interest income                             --              --         2,985,000            --          2,985,000
   Miscellaneous income                                2,759            --            13,417            --             21,323
   Interest income                                   393,223          49,229       1,099,704         176,703        1,427,702
   Interest expense                                  (22,657)        (17,258)        (56,584)        (46,039)        (264,841)
                                                ------------    ------------    ------------    ------------     ------------

Net Loss                                        $ (2,714,097)   $ (2,291,130)   $(18,063,609)   $ (6,288,775)    $(39,880,334)
                                                ============    ============    ============    ============     ============

Basic and Diluted Net Loss Per Common
   Share                                        $       (.14)   $       (.15)   $       (.98)   $       (.42)

Weighted Average Number of Shares of
   Common Stock Outstanding                       19,252,231      15,238,186      18,436,491      14,924,168
                                                ============    ============    ============    ============

</TABLE>


                 The Notes to Consolidated Financial Statements
                    are an integral part of these statements.


                                       4
<PAGE>


               GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
<TABLE>
<CAPTION>



                                                         For the Nine Months Ended       Cumulative From
                                                                 April 30,              November 2, 1995
                                                        ----------------------------   (Date of Inception)
                                                            2001            2000       to April 30, 2001
                                                        ------------    ------------   -------------------

Cash Flows From Operating Activities:
<S>                                                     <C>             <C>               <C>
Net loss                                                $(18,063,609)   $ (6,288,775)     $(39,880,334)
   Adjustments to reconcile net loss to
     net cash used in operating activities:
       Depreciation and amortization                          77,641          82,176           288,318
       Minority interest income                           (2,985,000)           --          (2,985,000)
       Reduction of notes receivable - common
         stock in exchange for services rendered                --           287,373           423,882
       Common stock issued for services rendered             662,504            --           1,903,232
       Stock options and warrants issued for
         services rendered                                      --           924,350         3,102,024
       Preferred stock issued for services rendered             --              --                 100
       Founders shares transferred for services
         rendered                                               --              --             353,506
       Changes in operating assets and liabilities:
         Miscellaneous receivables                            15,703         157,788            43,576
         Other current assets                                (92,703)         35,188          (195,451)
         Accounts payable and accrued liabilities           (396,438)        703,660         1,615,880
         Other, net                                             --              --             110,317
                                                        ------------    ------------      ------------
           Net Cash Used in Operating Activities         (20,781,902)     (4,098,240)      (35,219,950)

Cash Flows From Investing Activities:
   Purchase of property and equipment                     (1,480,492)        (98,970)       (2,154,446)
   Purchases of intangibles                                 (174,252)           --            (443,751)
   Change in restricted cash                                    --              --              (5,595)
   Purchase of short-term investments, net               (22,994,261)        (19,456)      (26,960,524)
   Change in deposits                                         27,879          (4,225)           29,998
   Change in notes receivable - common stock                  (4,874)           --              (8,992)
   Change in due from related parties                           --            76,165        (2,255,197)
   Other, net                                                   --              --              89,683
                                                        ------------    ------------      ------------
           Net Cash Used in Investing Activities         (24,626,000)        (46,486)      (31,708,824)

Cash Flows From Financing Activities:
   Proceeds from issuance of long-term debt                     --              --             993,149
   Repayment of long-term debt                                (2,943)       (391,735)         (963,719)
   Change in due to related parties                             --              --             154,541
   Proceeds from issuance of warrants                        494,250            --             494,250
   Proceeds from minority interest investment              2,985,000            --           2,985,000
   Proceeds from issuance of common stock, net            28,525,909       2,037,816        53,188,129
   Proceeds from issuance of preferred stock, net         12,015,000            --          12,015,000
   Purchase and retirement of common stock                      --              --            (119,066)
                                                        ------------    ------------      ------------
           Net Cash Provided By Financing Activities      44,017,216       1,646,081        68,747,284

Effect of Exchange Rates on Cash and Cash Equivalents        (18,294)          8,448           (22,585)
                                                        ------------    ------------      ------------
Net Increase (Decrease) in Cash and Cash Equivalents      (1,408,980)     (2,490,197)        1,795,925
Cash and Cash Equivalents, Beginning of Period             3,204,905       5,633,201              --
                                                        ------------    ------------      ------------
Cash and Cash Equivalents, End of Period                $  1,795,925    $  3,143,004      $  1,795,925
                                                        ============    ============      ============
</TABLE>

                 The Notes to Consolidated Financial Statements
                    are an integral part of these statements.


                                       5
<PAGE>

               GENEREX BIOTECHNOLOGY CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

1.     Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been
prepared pursuant to the rules and regulations for reporting Form 10-Q.
Accordingly, certain information and disclosures required by generally accepted
accounting principles for complete financial statements are not included herein.
The interim statements should be read in conjunction with the financial
statements and notes thereto included in the Company's latest Annual Report on
Form 10-K.

Interim statements are subject to possible adjustments in connection with the
annual audit of the Company's accounts for the fiscal year 2001; in the
Company's opinion, all adjustments necessary for a fair presentation of these
interim statements have been included and are of a normal and recurring nature.

2.      Revenue Recognition

Contract revenue from collaborative research agreements is recorded when earned
and as the related costs are incurred. Payments received, which are related to
future performance, are deferred and recognized as revenue when earned over
future performance periods. In accordance with contract terms, up-front and
milestone payments from collaborative research agreements are considered
reimbursements for costs incurred under the agreements, and accordingly, are
generally recognized based on actual efforts expended over the remaining terms
of the agreements.

3.     Comprehensive Income/(Loss)

The Company has adopted the provisions of Statement No. 130, Reporting
Comprehensive Income, which modifies the financial statement presentation of
comprehensive income and its components.

Comprehensive loss, which includes net loss and the change in the foreign
currency translation account during the period, for the nine months ended April
30, 2001 and 2000, was $18,182,264 and $6,250,621, respectively.

4.      Deferred Offering Costs

The Company has capitalized the value of warrants issued in conjunction with the
closing of an equity draw down agreement in August 2000. It is the current
intention of management that this asset will be amortized, on a pro rata basis,
against the proceeds derived from the issuance of common stock under this
agreement.



                                       6
<PAGE>



5.     Accounts Payable and Accrued Expense

Accounts payable and accrued expenses consist of the following:


                                              April 30,       July 31,
                                                2001            2000
                                            -----------    -------------
       Accounts Payable                     $   715,732    $     853,428
       Consulting Accruals                       13,453           77,086
       Litigation Accruals                       64,890          167,650
       Accrued Legal Fees                            --          106,118
                                            -----------    -------------
                Total                       $   794,075    $   1,204,282
                                            ===========    =============
6.     Pending Litigation

Sands Brothers & Co., Ltd. ("Sands"), a New York City-based investment banking
and brokerage firm, initiated arbitration against the Company under New York
Stock Exchange rules in January 1998. Sands claimed that it has the right to
purchase, for nominal consideration, approximately 1.5 million shares of the
Company's Common Stock. This claim is based upon a January 1997 letter agreement
which purportedly confirmed the terms of an agreement appointing Sands as the
exclusive financial advisor to Generex Pharmaceuticals, Inc. ("GPI") and
granting Sands the right to receive shares representing 17 percent of the
outstanding capital stock of GPI on a fully diluted basis. Following the
acquisition of GPI by GBC - Delaware, Inc., Sands claimed a right to receive
shares of GPI common stock that would, allegedly, now apply to the Company's
Common Stock. Sands also claimed that it is entitled to additional shares of the
Company as a result of the GBC - Delaware, Inc.'s acquisition of GPI
(approximately 460,000 shares), and $144,000 in fees under the terms of the
purported agreement.

Sands has never performed any services for the Company, and the Company and GPI
have denied that the individual who is alleged to have entered into the
purported agreement between Sands and GPI, had the authority to act on GPI's
behalf. Accordingly, the Company is defending against Sands' claim primarily on
the basis that no agreement has ever existed between GPI and Sands.

During a series of hearings before a NYSE arbitration panel commencing June 8,
1999, Sands amended its claim to include, in the alternative, an entitlement in
the form of an order of specific performance with regard to the issuance of the
warrant as discussed in the January 1997 letter.

By an award dated September 24, 1999, the panel awarded Sands $12,000 plus
$2,070 in interest, a declaratory judgment that the Company is required to issue
Sands a warrant for 1,530,020 shares in accordance with the January 1997 letter,
and denied all other relief and split the $22,800 in forum fees equally between
Sands and the Company. On January 13, 1999, Sands commenced a special proceeding
to confirm the Arbitration Award in New York State Supreme Court, New York
County. On November 10, 1999, the Company moved to vacate the arbitration award
on the grounds that the arbitration panel had exceeded its authority and had
manifestly disregarded the relevant law of agency in issuing the award. On March
20, 2000, the New York State Supreme Court granted Sands' petition to confirm
the arbitration award and denied the Company's motion to vacate the award. The
Court entered judgment against the Company. The Company appealed the lower
court's judgment to the New York State Appellate Division, First Department
("the Appellate Division"). On January 23, 2001, the Appellate Division modified
the judgment of the Supreme Court that had confirmed the arbitration award
against the Company. The Appellate Division affirmed the portion of the judgment
that had confirmed the granting of monetary relief of $14,070 to Sands but
modified the judgment to vacate the portion of the arbitration award directing
the issuance to Sands of a warrant to purchase 1,530,020 shares of the Company's
common stock. The Appellate Division held that the portion of the award
directing the Company to issue warrants to Sands is too indefinite to be
enforceable and remanded the matter to the arbitration panel for a final and
definite award with respect to such relief or its equivalent (including possibly
an award of monetary damages). A hearing before the arbitration panel for such
purpose has been scheduled for June 19, 2001. The Company believes that the
ultimate legal and financial liability of the Company, including a range of
possible losses with respect to the award, cannot be estimated at this time.
Therefore, no provision has been recorded in the accompanying financial
statements. Furthermore, it is management's belief that the final outcome is not
reasonably likely to have a material adverse effect on the Company's
consolidated financial position.


                                       7
<PAGE>

In February 1999, MQS, Inc., a former consultant to the Company, commenced a
civil action against the Company in the United States District Court, District
of New Jersey, claiming that 242,168 shares of the Company's Common Stock and
$243,066 are due to it for services, which it rendered through December 22,
1998. MQS also claims compensation on a quantum merit basis for the value of its
services, and for punitive damages. In January 2001, the Company entered into a
settlement agreement with MQS, whereby the Company paid the plaintiff certain
amounts in cash and common stock that are not material to the Company's
consolidated results of operations or consolidated financial position and
whereby the claims of the parties were dismissed without prejudice.

In February 2001, Subash Chandarana, a former business associated of Dr. Pankaj
Modi, and an entity named Centrum Technologies, Inc. commenced a legal
proceeding in the Ontario superior court of Justice against the Company and Dr.
Modi, seeking, among other things, damages for alleged breaches of contract and
tortuous acts related to a business relationship between Chandarana and Dr. Modi
that ceased in July 1996. The plaintiff's statement of claim also seeks to
enjoin the use, if any, by the Company of three patents owned by Centrum
Technologies, Inc. The Company cannot at this time predict the ultimate outcome
of this matter.

With respect to all litigation, as additional information concerning the
estimates used by the Company become known, the Company reassesses its position
both with respect to accrued liabilities and other potential exposures.
Estimates that are particularly sensitive to future change relate to legal
matters, which are subject to change as events evolve and as additional
information becomes available during the administration and litigation process.

7.     Net Loss Per Share

Basic EPS and Diluted EPS for the nine and three months ended April 30, 2001 and
2000 have been computed by dividing the net loss for each respective period by
the weighted average shares outstanding during that period. All outstanding
warrants and options have been excluded from the computation of Diluted EPS as
they are antidilutive.








                                       8
<PAGE>



  8.  Supplemental Disclosure of Cash Flow Information
<TABLE>
<CAPTION>

                                                                                   For the Nine Months Ended
                                                                                             April 30,
                                                                                ----------------------------------
                                                                                      2001               2000
                                                                                ---------------     --------------

       Cash paid during the period for:
<S>                                                                             <C>                 <C>
              Interest                                                          $     56,584        $         252
              Income taxes                                                      $         --        $          --

       Disclosure of non-cash investing and financing activities:
              Long-term debt incurred in conjunction with acquisition
                of property and equipment                                       $         --        $     190,206
              The fair value of warrants issued as consideration for an
                equity financing agreement was capitalized as deferred
                offering costs                                                  $  3,406,196        $          --
              Reduction in due from related party through repayment
                of long-term debt                                               $         --        $       1,287
              Common stock issued in exchange for note receivable -
                common stock                                                    $    250,000        $          --
</TABLE>

9.     Transactions With Related Parties

The Company's change in "Due from Related Parties" for the nine months ended
April 30, 2001 represents only the effects of changes in April 30, 2001 exchange
rates versus those in effect at July 31, 2000.

10.    Stockholders' Equity

In partial consideration for an exclusive supply agreement with the manufacturer
of a key component of the Company's Rapidmist(TM) device, the Company issued
35,000 shares of the Company's Common Stock valued at $11.75 per share. As a
result of this transaction, $411,250 was included as a charge to operations
during the nine-month period ended April 30, 2001.

As consideration for entering into a $50 million equity draw-down agreement, the
Company issued warrants to purchase 568,647 shares of the Company's Common Stock
at an exercise price of $12.15 and an expiration date of August 2003. As a
result of this issuance, a deferred charge was recorded in the amount of
$3,406,196, which will be amortized pro-rata as the Company raises capital in
conjunction with the agreement.

In October 2000, the Company completed a private placement of 2,151,093 shares
of its common stock at $11.00 per share. Each investor also received a warrant
to purchase one share of the Company's Common Stock for every fifteen shares of
common stock purchased. The warrants have an exercise price of $13.20 and expire
in five years.


In January 2001, the Company entered into a securities purchase agreement with
Elan International Services, Ltd., a wholly owned subsidiary of Elan
Corporation, plc. The agreement called for the sale of the following: (1) 1,000
shares of a newly-created series of the Company's preferred stock, captioned
"Series A Preferred Stock"; (2) 344,116 shares of the Company's Common Stock;
and (3) a warrant to purchase up to 75,000 shares of the Company's Common Stock.
The aggregate purchase price for these securities was $17,015,000. Certain
amounts from these proceeds were used to fund the Company's joint venture with
Elan International Services, Ltd. (See Note 11).


                                       9

<PAGE>

11.     Generex (Bermuda), Ltd.

On January 16, 2001, the Company established a joint venture with Elan
International Services, Ltd. ("EIS"), a wholly owned subsidiary of Elan
Corporation, plc (EIS and Elan Corporation, plc being collectively referred to
as "Elan"). Through the joint venture, the parties will pursue the application
of certain of the Company's and Elan's drug delivery technologies, including the
Company's platform technology for the buccal delivery of large molecule drugs,
to pharmaceutical products for the treatment of prostate cancer, endometriosis
and/or the suppression of testosterone and estrogen. The parties will conduct
the joint venture through Generex (Bermuda), Ltd., a Bermuda limited liability
company. The parties are free to develop other products on their own outside the
field of the joint venture.

The Company applied the $12,015,000 that it received from EIS for the shares of
the Company's Series A Preferred Stock to acquire 6,000 shares of Generex
(Bermuda) Ltd. common stock and 3,612 shares of convertible preferred stock,
representing an 80.1% equity ownership interest in Generex (Bermuda) Ltd. At the
same time, EIS remitted $2,985,000 to purchase 2,388 shares of Generex (Bermuda)
Ltd. Convertible preferred stock, representing a 19.9% equity ownership interest
in Generex (Bermuda) Ltd.

EIS has the option to exchange the 1,000 shares of the Company's Series A
Preferred Stock for 3,612 shares of the Company's convertible preferred shares
of Generex (Bermuda), Ltd. which represents 30.1% of the Company's equity
ownership in Generex (Bermuda) Ltd. Upon exercise, both parties would each own
50% of Generex (Bermuda) Ltd.

The parties intend to select at least one pharmaceutical product for research
and development under the joint venture by January 2002. The parties will
establish a research and development plan and budget upon selection of the
pharmaceutical product that will be the initial focus of the joint venture.
Generex (Bermuda), Ltd. has been granted rights to use the Company's buccal
delivery technology and certain Elan drug delivery technologies for purposes of
the joint venture. Using the funds from the initial capitalization, Generex
(Bermuda) Ltd. paid a nonrefundable license fee of $15,000,000 to Elan in
consideration for being granted rights to use the Elan drug delivery
technologies.

The Company expensed the entire cost of the license as a research and
development expense because of the uncertainties surrounding the future
realization of revenue from the use of the license.

12.     Subsequent Events

Effective May 4, 2001, the Board of Directors adopted and approved the 2001
Stock Option Plan, subject to stockholder approval. This plan provides for the
grant of options to employees, consultants and advisors, and directors. In
conjunction with the adoption of this plan, the Company granted 985,000 options
to purchase shares of the Company's Common Stock at a price of $5.19. Included
in this grant were 145,000 options granted to consultants and advisors which
resulted in a charge to operations of $523,450.

In May 2001, the Company granted options under its 2000 Stock Option Plan to
employees to purchase 355,000 shares of the Company's Common Stock at a price of
$7.56 per share. The Company also granted options under the 2000 Stock Option
Plan to a consultant to purchase 15,000 shares of common stock at $7.56 per
share. As a result of this grant, a charge to operations of $49,200 was
recognized.


                                       10


<PAGE>

Effective May 21, 2001, the Company increased the number of members of the Board
of Directors from six to seven.

On May 3, 2001, three officers of the Company, who are also directors and
stockholders, each borrowed $334,300 from the Company. These loans bear interest
at 8.5 percent per annum, and are payable in full on May 1, 2002, together with
all accrued and unpaid interest.

Item 2.           Management's Discussion and Analysis of Financial
                  Condition and Results of Operations

Forward Looking Statements

         We have made statements under the captions "Management's Discussion and
Analysis of Financial Condition and Results of Operations" and elsewhere in this
Report that are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements do not describe
historical events or other facts but, rather, convey our management's current
expectations. Such statements usually are prefaced with forward-looking words
such as "may", "will", "expect", "anticipate", "believe," "estimate" and similar
terminology. Our forward-looking statements address, among other things:

         o        the status of activities under our development and license
                  agreement with Eli Lilly and Company (the "Lilly Agreement");

         o        the status of activities under our joint venture with Elan
                  International Services, Ltd., a wholly-owned subsidiary of
                  Elan Corporation, plc;

         o        our other clinical and product development programs and other
                  aspects of our business plans;

         o        our financing goals, plans and future needs; and

         o        our expectations of when regulatory approvals will be received
                  or other actions will be taken by parties other than us.

Management's current expectations are subject to a number of factors and
uncertainties that could cause actual results or future conditions to differ
materially from those expressed in or implied by our forward-looking statements.
Thus, we caution investors that the forward-looking statements contained in this
report must be interpreted and understood in light of conditions and
circumstances that exist as of the date of this report. We expressly disclaim
any obligation or undertaking to update or revise forward-looking statements
made in this report to reflect any changes in management's expectations
resulting from future events or changes in the conditions or circumstances upon
which such expectations are based.

General

         Corporate History. We were incorporated in Delaware in September 1997
for the purpose of acquiring Generex Pharmaceuticals, Inc., a Canadian
corporation formed in November 1995 to engage in pharmaceutical and
biotechnological research and other activities. Our acquisition of Generex
Pharmaceuticals was completed in October 1997 in a transaction in which the
holders of all outstanding shares of Generex Pharmaceuticals exchanged their
shares for shares of our Common Stock.



                                       11
<PAGE>

         In January 1998, we participated in a "reverse acquisition" with Green
Mt. P. S., Inc., a previously inactive Idaho corporation formed in 1983. As a
result of this transaction, our shareholders (the former shareholders of Generex
Pharmaceuticals) acquired a majority (approximately 90%) of the outstanding
capital stock of Green Mt., we became a wholly-owned subsidiary of Green Mt.,
Green Mt. changed its corporate name to Generex Biotechnology Corporation
("Generex Idaho"), and we changed our corporate name to GBC Delaware, Inc.
Because the reverse acquisition resulted in our shareholders becoming the
majority holders of Generex Idaho, we were treated as the acquiring corporation
in the transaction for accounting purposes. Thus, our historical financial
statements, which essentially represented the historical financial statements of
Generex Pharmaceuticals, were deemed to be the historical financial statements
of Generex Idaho.

         In April 1999, we completed a reorganization in which we merged with
Generex Idaho. In this transaction, all outstanding shares of Generex Idaho were
converted into our shares, Generex Idaho ceased to exist as a separate entity,
and we changed our corporate name back to "Generex Biotechnology Corporation".
This reorganization did not result in any material change in our historical
financial statements or current financial reporting.

         Business History. We are engaged in the development of proprietary drug
delivery technology. Our principal business focus has been to develop a
technology for buccal delivery (absorption through the inner cheek walls) of
large molecule drugs, i.e., drugs composed of molecules with molecular weights
above a specified level. Large molecule drugs historically have been
administered only by injection because their size inhibits or precludes
absorption if administered by oral, transdermal, transnasal or other means.

         Our first product is an insulin formulation that is administered as a
fine spray into the oral cavity using a hand-held aerosol spray applicator.
Between January 1999 and September 2000, we conducted clinical trials on this
product in the United States, Canada and Europe. In September 2000, we entered
into an agreement to develop this product with Eli Lilly and Company ("Lilly").
Under the Lilly Agreement, Lilly is responsible for conducting clinical trials
of the product, securing regulatory approvals and marketing on a worldwide
basis. We received $1,000,000 in connection with our entry into the agreement
and will receive certain other initial fees and milestone payments subject to
the attainment of certain product development milestones, as well as royalty
payments based on product sales should any products be approved for commercial
sale. Lilly also has the option to develop certain additional products using our
buccal delivery technology depending on the success of the initial product.

         In January 2001, we established a joint venture with Elan International
Services, Ltd. ("EIS"), a wholly owed subsidiary of Elan Corporation, plc (EIS
and Elan Corporation, plc being collectively referred to as "Elan"). The joint
venture will pursue the application of certain of our and Elan's drug delivery
technologies, including our platform technology for the buccal delivery of
pharmaceutical products, for the treatment of prostate cancer, endometriosis
and/or the suppression of testosterone and estrogen. The parties intend to
select at least one pharmaceutical product for research and development under
the joint venture within one year's time. The parties will conduct the joint
venture through Generex (Bermuda), Ltd., a Bermuda limited liability company.

         In connection with the joint venture, EIS purchased 1,000 shares of a
new series of our preferred stock, designated as Series A Preferred Stock, for
$12,015,000. We applied the proceeds from the sale of the Series A Preferred
Stock to subscribe for an 80.1% equity ownership interest in Generex (Bermuda),
Ltd. EIS paid in capital of $2,985,000 to subscribe for a 19.9% equity interest
in Generex (Bermuda), Ltd. While we initially own 80.1% of the joint venture
entity, EIS has the right, subject to certain conditions, to increase its
ownership up to 50% by exchanging the Series A Preferred Stock for 30.1% of our
interest in the joint venture entity.


                                       12


<PAGE>

         Generex (Bermuda), Ltd. was granted non-exclusive licenses to utilize
our buccal delivery technology and certain Elan drug delivery technologies.
Using the funds from its initial capitalization, Generex (Bermuda), Ltd. paid a
non-refundable license fee of $15,000,000 to Elan in consideration for being
granted the rights to utilize the Elan drug delivery technologies.

         EIS also purchased 344,116 shares of our Common Stock for $5,000,000.
We may use the proceeds of this sale for any corporate purpose. If the joint
venture achieves certain milestones, we may require EIS to purchase an
additional $1,000,000 of our Common Stock at a 30% premium to the then
prevailing fair market value of our Common Stock.

         Our buccal delivery technology is a platform technology that we believe
has application to a significant number of large molecule drugs in addition to
insulin. During our current fiscal year and the next fiscal year, we expect to
begin development of additional products based on this technology that are not
covered by the Lilly Agreement or the joint venture with Elan.

Results of Operations

         We have been in the development stage since inception and have not
generated any operating revenues to date, other than $1,000,000 in revenues
received in connection with the Lilly Agreement.

         Our net loss for the quarter ended April 30, 2001, was $2,714,097
versus $2,291,130 for the corresponding quarter of the prior fiscal year. The
increased net loss is principally attributable to increased general and
administrative expenses (reflecting the costs of our 2001 annual meeting of
stockholders, increased investor relations and associated travel expenses and
increased executive compensation expenses, partially offset by decreased
payments to financial advisors). We also incurred a one-time expense due to a
settlement agreement with MQS, Inc., whereby we paid the plaintiff certain
amounts in cash and common stock. Interest income increased as a result of
increased cash and short-term investment balances, partially offsetting the
increased general and administrative expenses.

         Our net loss for the nine months ended April 30, 2001, was $18,063,609
versus $6,288,775 for the corresponding period of the prior fiscal year. The
increased net loss for the nine month period is principally attributable to the
accounting treatment for our joint venture with Elan, which resulted in a
$15,000,000 research and development expense for the license fee paid by Generex
(Bermuda) Ltd. to Elan for technology rights that was partially offset by
$2,985,000 of minority interest (reflecting Elan's 19.9% ownership of the joint
venture). Excluding the costs associated with the license fee, our net loss for
the nine months ended April 30, 2001 was comparable to our net loss for the same
period of the last fiscal year. During the nine months ended April 30, 2001, we
received $1,000,000 in revenues in connection with the Lilly Agreement and
significantly higher interest income (due to significantly higher average cash
and short-term investment balances). These amounts were offset by increased
general and administrative expenses for the fiscal 2001 period versus the fiscal
2000 period (reflecting the 2001 annual meeting costs, increased investor
relations and associated travel expenses, increased executive compensation
expenses and the settlement with MQS, Inc.).

Financial Condition, Liquidity and Resources

         To date we have financed our development stage activities primarily
through private placements of Common Stock and contract research and milestone
payments. At April 30, 2001, we had cash and short-term investments (primarily
notes of United States corporations) of approximately $28.75 million. At July
31, 2000, our cash and short term investments were approximately $7.17 million.
The increase in our cash and short term investments was primarily the result of
additional equity capital of approximately $22 million (net of financing costs
of approximately $1.66 million) from the October 2000 sale of 2,151,093 units of
our securities for cash at a price of $11.00 per unit, and $5 million from the
January 2000 sale to EIS of 344,116 shares of our Common Stock for cash at a
price of $14.529 per share.

                                       13


<PAGE>

         The only impact of the joint venture with Elan on our financial
condition and liquidity was the $5 million of additional equity capital. Our
cash position was not affected by the expenditure of $12,015,000 in proceeds to
subscribe for an 80.1% equity interest in Generex (Bermuda), Ltd., which we
received from the sale of 1,000 shares of Series A Preferred Stock to EIS.

         We believe that our cash on hand is sufficient to fund our operations
and capital expenditures for the current fiscal year and well into the next
fiscal year. Beyond that, we may require additional funds to support certain
clinical trials of our oral insulin formulation in Canada (for which we have
retained responsibility, subject to certain reimbursement rights, under the
Lilly Agreement), to fund our share of research and development expenses related
to our joint venture with Elan, and to fund other research and development
activities and general and administrative expenses. If we were unable to raise
additional capital as needed, we could be required to "scale back" or otherwise
revise our business plans. Any significant scale back of operations or
modification of our business plans due to a lack of funding could be expected to
materially and adversely affect our prospects.

         In the past we have funded most of our development and other costs with
equity financing. While we have been able to raise equity capital as required,
unforeseen problems with our clinical program or materially negative
developments in general economic conditions could interfere with our ability to
raise additional equity capital as needed, or materially adversely affect the
terms upon which such capital is available. We presently have a $50 million
equity "draw down" commitment from an investor pursuant to which, subject to
certain limitations and the satisfaction of certain conditions, we have the
right to require the investor to purchase up to $50 million of our Common Stock
at a 10% discount to the then current market price of the Common Stock. We also
have the right to require EIS to purchase $1 million of our Common Stock if the
joint venture achieves certain milestones, at a 30% premium to the then
prevailing market value of our Common Stock. We do not presently have any plans
to utilize the equity "draw down" commitment in the foreseeable future.

Transactions with Affiliates

         Prior to January 1, 1999, a portion of our general and administrative
expenses resulted from transactions with affiliated persons, and a number of
capital transactions also involved affiliated persons. Although these
transactions were not the result of "arms-length" negotiations, we do not
believe that this fact had a material impact on our results of operations or
financial position. Prior to December 31, 1998, we classified certain payments
to executive officers for compensation and expense reimbursements as "Research
and development - related party" because the executive officers received such
payments through personal services corporations rather than directly. After
December 31, 1998, these payments have been and will continue to be accounted
for as though the payments were made directly to the officers, and not as a
related party transaction. We do not foresee a need for, and therefore do not
anticipate, any related party transactions in the current fiscal year.

New Accounting Standards

         In June 1998, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 133, "Accounting for Derivative
Instruments and Hedging Activities" ("SFAS 133"). SFAS 133 establishes new
accounting and reporting standards for derivative financial instruments and for
hedging activities. SFAS 133 requires us to measure all derivatives at fair
value and to recognize them in the balance sheet as an asset or liability,
depending on our rights or obligations under the applicable derivative contract.
Subsequent to the issuance of SFAS 133, the FASB has received many requests to
clarify certain issues causing difficulties. In June 2000, the FASB issued SFAS
138, which responds to those requests by amending certain provisions of SFAS
133. The amendments include allowing foreign-currency denominated assets and
liabilities to qualify for hedge accounting, permitting the offsetting of
selected inter-entity foreign currency exposures that reduce the need for third
party derivatives and redefining the nature of interest rate risk to avoid
sources of ineffectiveness. We adopted SFAS 133 and the corresponding amendments
of SFAS 138 in the first quarter of the current fiscal year 2001. SFAS 133, as
amended by SFAS 138, did not have a material impact on our combined results of
operations, financial position or cash flows.

                                       14

<PAGE>

         In December 1999, the Securities and Exchange Commission issued Staff
Accounting Bulletin 101, "Revenue Recognition in Financial Statements" ("SAB
101"). SAB 101 provides guidance on the recognition, presentation and disclosure
of revenue in financial statements and requires adoption no later than the
fourth quarter of the current fiscal year 2001. We are presently evaluating the
impact of SAB 101 to determine what effect, if any, it may have on our financial
position and results of operations.


Item 3.           Quantitative and Qualitative Disclosures About Market Risk

         We are not presently subject to any material market risk exposures. We
are exposed to market risk associated with interest rate changes and changes in
the exchange rate between US and Canadian currencies.

         We have neither issued nor own any long term debt instruments, or any
other financial instruments as to which we would be subject to material risks.
At the present time, we maintain our cash in short term government or government
guaranteed instruments, short term commercial paper, interest bearing bank
deposits or demand bank deposits which do not earn interest. A substantial
majority of these instruments and deposits are denominated in US dollars, with
the exception of funds denominated in Canadian dollars on deposit in Canadian
banks to meet short term operating needs in Canada. We do not presently employ
any hedging or similar strategy intended to mitigate against losses that could
be incurred as a result of fluctuations in the exchange rates between US and
Canadian currencies.




                                       15

<PAGE>


Item 4.           Submission of Matters to a Vote of Security Holders

         The Annual Meeting of Stockholders of Generex Biotechnology Corporation
was held on April 23, 2001. At the meeting, 14,288,440 shares of Common Stock
were represented and entitled to vote. Generex stockholders elected nominees to
the Board of Directors, ratified the appointment of Deloitte & Touche LLP as
independent public accountants for the fiscal year ended July 31, 2001 and
ratified the Generex Biotechnology Corporation 2001 Stock Option Plan.

<TABLE>
<CAPTION>

                                                               Votes For                      Abstentions
                                                               ---------                      -----------
<S>                                                    <C>               <C>               <C>         <C>
      Election of nominees to
      Board of Directors for
      terms expiring in April, 2002

      Anna E. Gluskin                                         14,194,312                          104,532
      William M. Hawke, M.D.                                  14,214,167                           84,677
      Pankaj Modi, Ph.D.                                      14,193,462                          105,382
      E. Mark Perri                                           14,193,412                          105,432
      Rose C. Perri                                           14,186,962                          111,882
      Jan Michael Rosen                                       14,215,167                           83,677
      -----------------

                                                          Votes
                                                           For           Votes Against           Abstentions
                                                           ---           -------------           -----------
       Ratification of Deloitte & Touche LLP
       as Independent Public Accountants               14,228,864            63,420                6,560
       -----------------

                                                          Votes           Votes                          Broker
                                                           For           Against      Abstentions       Non-Votes
                                                           ---           -------      -----------       ---------
       Approval of Generex Biotechnology
       Corporation 2001 Stock Option
       Plan                                             7,799,968       1,290,227          43,270      5,165,361

</TABLE>




                                       16
<PAGE>


PART II. OTHER INFORMATION

Item 1.           Legal Proceedings


With regard to our pending legal proceeding with Sands Brothers & Co., Ltd., the
arbitration rehearing ordered by the New York State Appellate Division, First
Department has been scheduled for June 19, 2001. For a full description of the
foregoing legal proceeding, and all other legal proceedings against the Company,
see the Company's Report on Form 10-K for the year ended July 31, 2000, Report
on Form 10-Q for the quarter ended January 31, 2001, and Reports on Form 8-K
filed January 23, 2001 and January 25, 2001, which are incorporated herein by
reference.

Item  6.          Exhibits and Reports on Form 8-K

(a)      Exhibits.

                  None

(b)      Reports on Form 8-K.

         The following reports have been filed on Form 8-K and Form 8-K/A in the
quarter ended April 30, 2001:

         (1) The Company's Current Report on Form 8-K filed with the Commission
         on April 27, 2001.

         (2) The Company's Current Report on Form 8-K, filed with the Commission
         on January 23, 2001, as amended by a Form 8-K/A filed with the
         Commission on February 1, 2001.





                                       17
<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934, we
have duly caused this report to be signed on our behalf by the undersigned.

DATE:  June 13, 2001

                               GENEREX BIOTECHNOLOGY CORPORATION


                               By:    /s/ E. Mark Perri
                                  ---------------------------------------
                                    E. Mark Perri
                                    Chairman and Chief Financial Officer









                                       18